CMPS - Compass Pathways

-

$undefined

N/A

(N/A)

Compass Pathways NasdaqGS:CMPS COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Location: 33 Broadwick Street, London, W1F 0DQ, United Kingdom | Website: https://compasspathways.com | Industry: Medical Care Facilities | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

221M

Cash

260.1M

Avg Qtr Burn

-36.0M

Short % of Float

7.34%

Insider Ownership

13.64%

Institutional Own.

55.99%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.